Welcome To RobinsPost.com


Related News Videos From Youtube For:

Pracinostat and Acute Myeloid Leukemia - Preliminary Data is Encouraging

Pracinostat is a histone deacetylase (HDAC) inhibitor being developed for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this exclusive interview with Rare Disease Report, Guillermo Garcia-Manero, MD of University of Texas MD Anderson Cancer Center talks about data his group presented at American Society of Hematology (ASH) annual meeting showing the combination of pracinostat plus azacitidine may improve outcomes in older patients with AML. Reference Garcia-Manero G, Atallah, E, Odenike O et al, Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Presented at” American Society Hematology Annual Meeting; December 6-9,2014; SanFrancisco CA. Abstract 947.

Acute Myeloid and Lymphoid Leukemia

Acute Myeloid Leukemia -- Treatment

Immune Based Therapies for MDS and AML

Why curing cancer is so hard | Azra Raza | TEDxNewYork

The AML genome(s): Mutations in four dimensions

Classification and Prognosis in MDS

Facts about myelodysplastic syndrome

Dr. Garcia-Manero on Curing Patients With MDS and AML

Rigosertib in combination with azacitidine: a potential treatment for AML?

What is "MDS"? (Myelodysplastic Syndromes)